Trial · NCT03710291
Evaluation of Effect of TRC101 on Progression of Chronic Kidney Disease in Subjects With Metabolic Acidosis
NCT03710291, Phase 3, Terminated, Tricida, Inc.
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Evaluation of Effect of TRC101 on Progression of Chronic Kidney Disease in Subjects With Metabolic Acidosis. Trials, record NCT03710291. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT03710291
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Evaluation of Effect of TRC101 on Progression of Chronic Kidney Disease in Subjects With Metabolic Acidosis
- NCT number
- NCT03710291
- Status
- Terminated
- Phases
- Phase 3
- Enrollment
- 1,480 participants, actual
- Lead sponsor
- Tricida, Inc.
- Conditions
- Metabolic Acidosis, Chronic Kidney Disease
- Interventions
- TRC101, Placebo
- First posted
- 2018-10-18
- Last updated
- 2022-10-14
- Other registries' IDs
- eudract:2018-001303-36
Source ClinicalTrials.gov
Registered outcomes13
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Progression of chronic kidney disease | Through study completion, up to approximately 6 years. | Time to first occurrence of: a confirmed ≥40% reduction in eGFR; ESRD; renal death. |
| Secondary | Death (all-cause), ESRD or a confirmed ≥50% reduction in eGFR | Through study completion, up to approximately 6 years. | Time to first occurrence of: death (all-cause); ESRD; a confirmed ≥50% reduction in eGFR. |
| Secondary | Physical functioning (subjective) | 18 months after randomization. | Kidney Disease Quality of Life Physical Functioning Survey. |
| Secondary | Physical functioning (objective) | 18 months after randomization. | Repeated chair stand test. |
| Secondary | ESRD or renal death | Through study completion, up to approximately 6 years. | Time to ESRD or renal death. |
| Secondary | Primary outcome measure OR cardiovascular death | Through study completion, up to approximately 6 years. | Time to first occurrence of: a confirmed ≥40% reduction in eGFR; ESRD; renal death; cardiovascular death. |
| Secondary | Serum creatinine | Through study completion, up to approximately 6 years. | Time to first occurrence of a confirmed doubling of serum creatinine. |
| Secondary | ≥50% reduction in eGFR | Through study completion, up to approximately 6 years. | Time to first occurrence of a confirmed ≥50% reduction in eGFR. |
| Secondary | ≥40% reduction in eGFR | Through study completion, up to approximately 6 years. | Time to first occurrence of a confirmed ≥40% reduction in eGFR. |
| Secondary | All-cause hospitalization | Through study completion, up to approximately 6 years. | Frequency of all-cause hospitalization. |
1 to 10 of 13Source ClinicalTrials.gov
See all 13 registered outcomesOutcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers2
The papers the trial lists on ClinicalTrials.gov.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT03710291
GET https://conductscience.org/api/trials/v1/NCT03710291/registered